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Abstract
Lactoperoxidase (LPO) is the major consumer of hydrogen peroxide (H2O2) in the airways through its ability to oxidize
thiocyanate (SCN
2) to produce hypothiocyanous acid, an antimicrobial agent. In nasal inflammatory diseases, such as cystic
fibrosis, both LPO and myeloperoxidase (MPO), another mammalian peroxidase secreted by neutrophils, are known to co-
localize. The aim of this study was to assess the interaction of LPO and hypochlorous acid (HOCl), the final product of MPO.
Our rapid kinetic measurements revealed that HOCl binds rapidly and reversibly to LPO-Fe(III) to form the LPO-Fe(III)-OCl
complex, which in turn decayed irreversibly to LPO Compound II through the formation of Compound I. The decay rate
constant of Compound II decreased with increasing HOCl concentration with an inflection point at 100 mM HOCl, after
which the decay rate increased. This point of inflection is the critical concentration of HOCl beyond which HOCl switches its
role, from mediating destabilization of LPO Compound II to LPO heme destruction. Lactoperoxidase heme destruction was
associated with protein aggregation, free iron release, and formation of a number of fluorescent heme degradation
products. Similar results were obtained when LPO-Fe(II)-O2, Compound III, was exposed to HOCl. Heme destruction can be
partially or completely prevented in the presence of SCN
2. On the basis of the present results we concluded that a complex
bi-directional relationship exists between LPO activity and HOCl levels at sites of inflammation; LPO serve as a catalytic sink
for HOCl, while HOCl serves to modulate LPO catalytic activity, bioavailability, and function.
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Introduction
Myeloperoxidase (MPO) and lactoperoxidase (LPO) are ho-
mologous members of the mammalian peroxidase superfamily
which also include eosinophil peroxidase and thyroid peroxidase.
These enzymes share an overall 60–70% amino acid sequence
homology [1–3]. The heme moiety in the peroxidases is attached
to the enzymes through an imidazole nitrogen; its main function is
to catalyze the H2O2-dependent oxidation of halides and pseudo
halides to generate the corresponding hypohalous acid, in the
catalysis of oxidative reactions [4–6]. LPO is a monomeric protein
with a single polypeptide chain of 78.5 kDa, and uses the pseudo
halide, thiocyanate (SCN
2) as a preferred substrate to generate
hypothiocyanous acid (HOSCN) [6,7]. Whereas, MPO is a 150–
165 kDa, homodimer, each subunit comprising of a pair of light
and heavy chains, and uses chloride (Cl
2) as the preferred
substrate to generate hypochlorous acid (HOCl) [2,3,8]. The
reaction of peroxidases and the co-substrate H2O2 involves oxygen
transfer to Fe(III) to form a ferryl porphyrin p cation radical
(Fe(IV)=O
+pN; Compound I) intermediate as an initial step in the
classic peroxidase catalytic cycle [2,3,6,9]. Compound I is a short-
lived intermediate and is readily reduced to its 1 electron
equivalent, forming a ferryl intermediate (LPO-Fe(IV)=O;
Compound II) a longer-lived intermediate whose decay to ferric
state is considered to be the rate-limiting step during steady-state
catalysis [2,3,10].
Enhancements in peroxidase catalysis due to reduction of
compounds I and II have been noted with a series of organic and
inorganic substrates [10–13] and physiological reductants generating
cytotoxic oxidants and diffusible radical species [14,15]. In addition,
the heme moiety of mammalian peroxidases can accommodate a
large variety of molecules as a ligand of the iron cation, in whichtheir
bindings to the heme moiety inhibit the catalytic activity of the
enzymes [10–13]. For example, superoxide and O2 can serve as
ligands for Fe(III) and Fe(II) of peroxidases, respectively, to generate
ferrous dioxy complex (Fe(II)-O2 complex), Compound III [16–18].
Hypochlorous acid (HOCl) generated by MPO plays an
important role in killing microorganisms [19]. However, it is also
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posttranslational modification of target proteins, injure normal
tissues by bleaching the heme moieties of hemoproteins, and
oxidatively destroying electron transport chains [20–22]. The rate
of HOCl production by neutrophils has been shown to be as high
as 450 mM/h in an in vitro study, which may be less in an in vivo
model, due to scavenging actions of antioxidants [23,24]. Recent
studies have shown that catalytically active MPO and its oxidative
species are present in human atherosclerotic lesions [25–27]. This
implicates the enzyme involvement in low-density lipoprotein
oxidation in vivo [28]. It has also been shown that iron accumulates
in atherosclerotic lesions in a catalytically active form [29,30]. The
source of this iron is still unclear, but it is thought to result from
hemoglobin released from damaged red cells at sites of vascular
turbulence or in hemorrhagic atheromatous plaques [31].
Recently we have shown that under oxidative stress, MPO may
serve as a source of free iron through a mechanism that involves
heme depletion [32].
LPO and MPO, and their final products commonly participate
in tissue injury in a large number of inflammatory conditions, and
are used as markers for lung and atherosclerotic cardiovascular
diseases [1,2,33,34]. To further assess the potential physiological
relevance of HOCl interactions with LPO under conditions that
more closely mirror high-risk subjects, such as lung and heart
diseases, we investigated the effect of varying HOCl concentra-
tions on LPO-Fe(III) and LPO-Fe(II)-O2 catalysis in the absence
and presence of plasma levels of SCN
2. A variety of analytical
techniques including optical absorbance spectrophotometry, rapid
kinetics measurements, high performance liquid chromatography
(HPLC), free iron, and SDS-PAGE were utilized in this study. Our
results revealed that low levels of HOCl binding to LPO-Fe(III)
resulted in a rapid formation and decay of LPO Compounds I and
II, suggesting that LPO may serve as a catalytic sink for the
removal of HOCl. Increase in the levels of HOCl cause rapid
accumulation of LPO Compound II followed by heme destruction
and subsequent iron release and protein aggregation. Heme
destruction and protein aggregation can be partially or completely
prevented in the presence of increasing levels of SCN
2.
Results
Spectroscopic and rapid-kinetics characterization of the
interaction between HOCl and LPO-Fe(III)
Spectroscopic studies demonstrated that incubation of LPO-
Fe(III) and LPO Compound II with increasing concentration of
HOCl for 30 minutes caused LPO heme destruction, as judged by
a decrease and shift in the Soret peak at 412 and 432 nm,
respectively (Fig. 1 A and B). Fig. 1 insets show the percentage
recovery of LPO as a function of HOCl. We next utilized the
diode array stopped-flow instrument to investigate how HOCl
influences the LPO catalytic activity and function as may occur
under inflammatory condition. Rapid mixing of a buffered
solution supplemented with 6 mM LPO-Fe(III) with an equal
volume of a similar solution supplemented with 25 mM HOCl in
the absence of co-substrates resulted in the rapid formation of a
transient complex that displayed a Soret absorbance at 410 nm
(Fig. 2A). This spectrum differs from that of ferric LPO, whose
Soret maxima is centered at 412 nm. The spectrum of the
intermediate initially formed following addition of HOCl to LPO-
Fe(III) is consistent with formation of LPO Compound I [35]. This
LPO intermediate was formed within 30 ms after mixing at 10uC,
but was unstable and rapidly converted partially into a more stable
intermediate within 0.5 s, as characterized by a partial time-
dependent shift of the Soret band at 412 to 432 nm, together with
slight modification in the visible region from 500 to 700 nm.
These spectral changes are consistent with the partial formation of
LPO Compound II, as shown in Fig. 2B. LPO Compounds I and
II were unstable and converted gradually to the LPO-Fe(III),
within 1 minute of initiating the reaction (Fig. 2C). Rapid mixing
of a solution of LPO-Fe(III) with an equal volume of a 50 mMo f
HOCl show similar results except that formation of Compound I
(Fig. 2D) is much faster and completely converted to Compound II
Figure 1. Optical absorbance spectra for concentration dependent of HOCl-mediated heme depletion of LPO-Fe(III) and LPO
Compound II. Spectral traces were recorded after 2 h of incubation of a fixed amount (1.5 mM) of LPO-Fe(III) (Panel A) and LPO Compound II (Panel
B) with increasing concentration of HOCl (0, 25, 50, 100, 150, 175, 200 and 300 mM), at 25uC. Arrows in Panel A and B indicate the direction of spectral
change. The LPO recovery estimated from the absorbance values at 432 from each spectral scan recorded in the Panels A and B are plotted versus
HOCl concentration (Panel A and B insets). These data are representative of three independent experiments.
doi:10.1371/journal.pone.0027641.g001
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Rapid mixing of a solution of LPO-Fe(III) with higher HOCl
concentrations (e.g. 800 mM) shows faster formation of Compound
I (Fig. 2G), which is converted completely to Compound II in the
next 2 s (Fig. 2H). Formation of Compound II by HOCl was
accompanied by a marked decrease and flattening in the Soret
absorbance region within a minute of initiating the reaction
(Fig. 2I), suggesting heme degradation. These spectral changes
may also suggest that, under these conditions, the majority of LPO
was converted to Fe(IV)=O complex before heme destruction.
To determine the role of the LPO-Fe(II)-O2 complex in
catalytic activity, as well as to further our understanding of the
potential role of LPO in catalase-like function, the direct reaction
between LPO-Fe(II)-O2 with HOCl was carried out using rapid
kinetic measurements. As shown in Figs. 3A, addition of a slight
molar excess of H2O2 to LPO-Fe(III) caused immediate LPO
Compound III formation, as judged by a shift in the Soret
absorption peak from 412 to 424 nm, and the appearance of
additional absorbance peaks in the visible range at 561 and
595 nm (17,38). This intermediate is relatively stable. Rapid
mixing of a buffer solution supplemented with 6 mM LPO-Fe(II)-
O2 against a buffer solution supplemented with 300 mM of HOCl
in the absence of co-substrates (Figs. 3A,B) led to the accumulation
of Compound II within the first 28 s of initiating the reaction via
the transient initial formation of Compound I. Compound II that
accumulated during the reaction then decay back to LPO-Fe(III)
within the next 600 s (Fig. 2B). Similar behavior was observed
when LPO-Fe(II)-O2 solution was mixed with 800 mM HOCl,
except that compound II exhaustion occurred through a heme
destruction pathway (Fig. 3D,E). At all HOCl concentrations
tested, spectral transitions between each intermediate formed
revealed distinct and well-defined isosbestic points (Figs. 2 and 3).
Thus sequential formation and decay of LPO intermediates within
the peroxidase cycle occur at sufficiently different rates to enable
Figure 2. Formation of LPO Compound I and II and their exhaustion through the reactions of LPO-Fe(II) with increasing
concentration of HOCl. Rapid-scanning diode array spectra were recorded during the reaction of LPO-Fe(III) (3 mM) with a buffer solution
containing 25 mM (Panels A, B, and C), 50 mM (Panels D, E, and F), and 800 mM (Panels and G, H, and I) HOCl, at 10uC. Selected spectra were omitted
from each panel for clarity. Arrows in the panels indicate the direction of spectral change over time. The time of each collected spectrum after
initiation of the reaction is indicated in seconds. The data are representative of three independent experiments.
doi:10.1371/journal.pone.0027641.g002
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stopped-flow methods.
We next utilized stopped-flow spectroscopy to investigate how
HOCl interacts with catalytic intermediates of LPO. The influence
of HOCl on the kinetics of LPO Compound II build-up, duration
and decay were examined following rapid mixing of enzyme and
various concentrations of HOCl. The time courses for the
formation and decay of Compounds I and II of LPO in the
absence of SCN
2 were detected by monitoring the absorbance
change at 412 and at 430 nm (data not shown). At all HOCl
concentration tested, there was a monophasic decrease in
absorbance at 412 nm, attributed to buildup of LPO-Fe(III)-OCl
complex formation, followed by a slower, essentially monophasic
decrease attributed to heme destruction. As shown in Fig. 4, Panel
A, the plot of the observed rate (kobs) versus HOCl concentration
was linear, with positive intercept indicating that the reaction is
reversible in nature yielding combination and dissociation rate
constants estimated from the slope and intercept of
12.1 mM
21 s
21 and 18 s
21, respectively. The subsequent increases
in absorbance at 432 nm, attributed to Compound II formation,
were also best fitted to a single exponential function. The plot of
the observed rate constant as a function of HOCl concentration
was linear with y-intercept close to zero and yielded a second order
rate constant of 0.014 mM
21 s
21 (Fig. 4B).
At lower HOCl concentration, HOCl accelerated the decay of
Compound II to LPO-Fe(III) (Fig. 2). The rate constant for decay
of Compound II decreased with increasing HOCl concentration
with an inflection point at 100 mM HOCl, after which the decay
rate increased (Fig. 4C). This point of inflection is the critical
concentration of HOCl beyond which HOCl switches its role,
from mediating destabilization of LPO Compound II to LPO
heme destruction. At HOCl higher than the inflection point, the
rate of LPO Compound II destruction increased in a linear
manner as a function of HOCl concentration line extrapolation
was close to zero (Fig. 4C inset; dashed line), indicating that the
heme destruction is an irreversible process. The second order rate
of HOCl-mediated heme destruction, estimated from the slope
(Fig. 4C inset), yielding a second order rate constant of
1610
24 mM
21 s
21. Finally, HOCl significantly accelerated the
rate of LPO-Fe(II)-O2 decay in a concentration-dependent
fashion. Plots of HOCl concentration vs. observed rates of LPO-
Fe(II)-O2 destruction demonstrated linear kinetics and yielded
second order rate constants of 4610
24 mM
21 s
21 (Fig. 4D).
SCN
2 modulates HOCl-mediated LPO heme degradation
To test the ability of SCN
2 in modulating HOCl-mediated
LPO heme degradation, in a 1 ml (final volume) phosphate buffer
solution, we first mixed a fixed amount of LPO (1.5 mM) with
Figure 3. Diode array spectral changes for the reaction of LPO compound III with increasing concentration of HOCl. Rapid-scanning
diode array spectra were recorded during the reaction of LPO Compound III (3 mM) with a buffer solution containing 300 mM (Panels A and B) and
840 mM (Panels and G, H, and I) HOCl, at 10uC. Arrows in the panels indicate the direction of spectral changes over time. The time of each collected
spectrum after initiation of the reaction is indicated in seconds. The dashed line spectrum is the spectra of the LPO-Fe(III). The first spectrum
corresponds with the initial formation of Compound III, which was generated by mixing LPO-Fe(III) with 200 mMH 2O2. The experiments shown are
representative of three.
doi:10.1371/journal.pone.0027641.g003
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2 (0 to 300 mM) and then the
reaction mixtures received fixed concentration of HOCl (300 mM).
After 2 hours incubation, the full absorbance spectrum (from 300–
700 nm) for each solution mixture was collected, and the
percentage recovery in the LPO Soret absorbance peak was
plotted as a function of SCN
2 concentration. The percentage
recovery increased linearly and maximized (,85%) at 75 mM
SCN
2, a ratio of 4:1 HOCl:SCN
2 (Fig. 5).
HOCl-mediated heme destruction, protein aggregation
and free iron release in LPO
As HOCl is thought to oxidize the heme moiety of LPO, we
examined whether these spectral transformations that are
apparent from our UV–visible spectral analysis may represent
the oxidation, free iron release, and subsequently protein
aggregation. To investigate how the flattening in the Soret
absorbance peak at 412 nm, in HOCl treated samples, is related
to modification in the protein moiety of LPO after HOCl
treatment, using reducing SDS-PAGE (Fig. 6), we analyzed the
protein aggregation in LPO (1.5 mM final) after treatment with 25
to 300 mM of HOCl, by SDS-PAGE. The LPO monomer band
intensity decreases slightly until quite near the 1:100 LPO:HOCl
ratio, followed by steep plunge till 1:200 LPO:HOCl ratio after
which it saturates. In contrast, the monomer:oligomer band
intensity showed a steady increase till 1:200 LPO:HOCl ratio after
which it saturates. With the largest amounts of HOCl, the distinct
pattern of aggregation disappeared, producing smears over the
entire length of the lanes. This could be attributed either to the
formation of aggregates that were too large to enter the separating
gel, or to fragmentation. Bonini et al., have obtained similar
aggregation patterns when catalase was treated with HOCl (39).
Free iron accumulation when assayed by ferrozine (as detailed in
Materials and Methods) showed a linear increase as a function of
HOCl concentration (Fig. 7).
HPLC analysis of heme degradation products from LPO
Heme by itself does not have any intrinsic fluorescence, but
porphyrin derivatives generated due to oxidative fragmentation of
heme do have an intrinsic fluorescence. We used this property to
analyze the heme fragmentation pattern after HOCl treatment of
LPO. Based on a previously published report we chose to monitor
the chromatograms at excitation 321 nm and emission 465 nm
[36,37]. Fig. 8 shows the chromatograms when LPO was treated
with different molar ratios of HOCl. We incubated a fixed amount
of LPO (10 mM) with increasing molar ratios of HOCl (1:25, 1:200
and 1:400). When LPO was reacted with HOCl, there was a
progressive accumulation of new heme degradation products (as a
function of HOCl concentration) eluting at earlier time. By
comparing the chromatograms we concluded that HOCl treat-
ment led to the formation of at least three different fluorescent
degradation products with retention times of 2, 3.3, 5 and
8 minutes, respectively. The appearance of new earlier eluting
Figure 4. Plot of observed rate constants of various interme-
diates that formed upon mixing of LPO-Fe(III) or LPO-Fe(II)-O2
against increasing concentration of HOCl. The observed rates of
LPO-Fe(III)-OCl formation monitored at 432 nm (Panel A); Compound II
accumulation (Panel B); and Compound II decay(Panel C); as for Fig. 2,
were plotted as a function of HOCl concentration. In Panel C, the close
triangle represent kinetic parameters for Compound II decay to LPO-
Fe(III), while the close circles represent kinetic parameters for
Compound II destruction. The inset shows the rate of heme destruction,
the curve was extrapolated to zero. Panel C is the plots of the observed
rates for the LPO Compound III heme destruction versus HOCl
concentration, monitored at 424 nm. The data are representative of
three separate experiments.
doi:10.1371/journal.pone.0027641.g004
Figure 5. SCN
2 prevents HOCl mediated LPO heme degrada-
tion. Fixed amount of LPO (1.5 mM) was incubated with increasing
concentrations of SCN
2 (0–300 mM) and the reaction mixtures then
treated with fixed amount of HOCl (300 mM). After incubating the
reaction for 2 hours, absorbance spectra were collected. The percent-
age protection in LPO heme content was calculated from the
absorbance at 412 nm and plotted against SCN
2 concentration. The
inflection point (which occurs at 4:1 HOCl:SCN
2 ratio) is marked by the
dashed line with arrow. The data are averages of three independent
experiments.
doi:10.1371/journal.pone.0027641.g005
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degradation products with decreasing hydrophobicity generated
by fragmentation of the tetrapyrrole ring of the heme.
Discussion
LPO is present in different biological fluids and epithelial
surfaces, including the oral cavity and the airways [38–40], as part
of the innate defense system. In the human oral cavity, the LPO
defense system usually works in concert with other local defenses,
like MPO, lysozyme and lactoferrin, to ensure tissue protection
[40,41]. Although LPO and MPO function to keep sterility of the
airway system in the setting of constant exposure to inhaled debris
and potential pathogens, they may also play a role in tissue defense
against oxidative stress through their ability to scavenge excess
H2O2 and protect the airway epithelium from its toxicity [38,42].
This is especially important in the airways, where catalase is
present in the peroxisomal system, but not secreted in the luminal
fluid [43], thereby making mammalian peroxidases the main
H2O2 scavengers. In addition to higher levels of LPO and MPO,
patients with asthma, cystic fibrosis, and chronic obstructive
pulmonary disease display higher levels of free iron in their lung
compared to normal subjects [44–46]. As yet the source of the free
iron is still unclear, but one major source of free iron may be the
destruction of heme moiety from hemoproteins and the release of
the iron residing in active sites of these proteins. Evidence for the
involvement of the LPO/HOCl system as this source is the high
affinity of LPO-Fe(III) towards HOCl and the ability of HOCl to
destroy the catalytic center of the enzyme, which is, in this case,
the heme moiety.
Figure 6. Protein aggregation of LPO treated with different HOCl concentrations. Upper panel depicts the reducing SDS-PAGE of LPO
treated with HOCl, showing a decrease in the main LPO band, and a concomitant increase of high molecular weight aggregates. Lower panel displays
a plot showing the variations of pixel intensity of LPO monomer (closed diagonal) and high molecular weight aggregates (closed square) as a
function of HOCl concentration. Reaction was carried-out by mixing a buffered solution of LPO (1.5 mM final) with HOCl, and the gel was run after
60 minutes incubation, at 25uC. These data are representative of three independent experiments.
doi:10.1371/journal.pone.0027641.g006
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of LPO compound I through the reaction of LPO-Fe(III) with
HOCl is extremely fast in contrast to a two electrons reduction of
H2O2, and occurs in a concentration dependent fashion [47]. The
results of the present study confirmed and extended these findings,
and demonstrate that HOCl not only mediates the formation of
LPO Compound I, but it also mediates LPO protein aggregation,
heme destruction, and subsequent iron release. During continuous
monitoring the reaction of OCl
2 with LPO-Fe(III) with diode
array stopped-flow methods, rates of LPO Compound I formation
were dramatically accelerated as a function of HOCl concentra-
tion. HOCl-dependent formation of Compound I was catalytic,
since low levels of OCl
2 were required, relative to the
concentration of LPO used. Furthermore, HOCl-dependent
formation of LPO Compound I occurred in concentrations of
HOCl that span both the physiological and pathophysiological
range. It is possible that the heterolytic cleavage of the O-Cl bond
in an LPO-Fe(III)-OCl intermediate preferentially occur at neutral
conditions, to degrade HOCl and form a ferryl porphyrin radical
cation LPO-Fe(IV)=O
N intermediate. This intermediate is highly
unstable and immediately decays to form LPO-Fe(IV)=O
complex. The degree of Compound II accumulation, stability,
and its exhaustion pathway depend mainly on the HOCl
concentration used. The transition of the pathway of Compound
II exhaustion is reflected by the deflection in the decay rate with a
HOCl critical concentration of 100 mM (Fig. 3C). Below this
concentration, HOCl is capable of destabilizing LPO Compound
II and did not cause LPO heme destruction. Concentrations of
HOCl generated by the activated blood neutrophils range between
150–425 mM HOCl per h [23,48]. Thus, the beneficiary role of
LPO is not only limited to scavenging of HOCl, but also activating
LPO by accelerating the conversion of Compounds II and III to
LPO-Fe(III), the active form of the enzyme. These finding may
display an important application in biological systems, since
scavenging HOCl by LPO may protect the airway epithelium
from its toxicity. But above the critical concentration, HOCl
irreversibly mediates heme destruction and subsequent free iron
liberation as well as protein aggregation. Consistent with this
notion, the colorimetric ferrozine-based assay for quantitation of
free iron showed a corresponding increase in free iron production
as a function of HOCl concentration. The toxic effect of free iron
is due to its ability to generate other ROS, such as the O2
N2,
H2O2, and the hydroxyl radical (
NOH), that mediate cellular
mitochondria poisoning, lipid peroxidation, and oxidative phos-
phorylation uncoupling [49–51]. Free iron damages blood vessels
and induces vasodilation with increased vascular permeability,
leading to hypotension and metabolic acidosis [31,52]. Under
many pathological conditions such as atherosclerosis, endometri-
osis, and cancer, where MPO has been known to play a role, there
have been reports of significant free iron accumulation [53,54].
Compound II is the major inactive intermediate that accumu-
lates prior to heme destruction. It is not clear whether the
formation of LPO Compound II is essential for HOCl-mediated
heme destruction directly or else possibly indirectly after
incorporation into another intermediate, more susceptible to
heme destruction than Compound II. The high stability of
Compound II during the peroxidase cycle makes the LPO
tetrapyrrole ring more susceptible to a direct HOCl attack. We
propose that HOCl mediated cleavage of the tetrapyrrole moiety
occurs through a radical based mechanism, as shown in our
previous studies [36,37]. Alternatively, the heme moiety of
Compound II, in the presence of HOCl, could be destroyed
through the formation of LPO-Fe(III)-OO
2 radical [55]. Under
these circumstances, the formation rate of the Compound II is
comparable or slower that the decay of this intermediate, therefore
the buildup of the LPO-Fe(III)-OO
2 radical cannot be seen, and
the conversion of Compound II to LPO-Fe(III)-OO
2 is the rate
limiting step and occurs independently of the HOCl concentra-
tion. LPO heme destruction is also confirmed by HPLC analysis,
which revealed that at least three fluorescent heme degradation
Figure 7. Release of free iron from LPO following treatment
with HOCl. 10 mM of LPO-Fe(III) were incubated with increasing HOCl
concentrations (0, 175, 350, 700, 1050, 1400, and 2100 mM) for
30 minutes, at 25uC. Free iron was assayed colorimetrically using
ferrozine (for details see Materials and Methods section). Experiments
were carried out in sodium phosphate buffer (0.2 M at pH 7.0). These
data are representative of three independent experiments.
doi:10.1371/journal.pone.0027641.g007
Figure 8. Treatment of LPO with HOCl leads to the generation
of fluorescent heme degradation products. LPO (1.5 mM) was
treated with increasing ratios of HOCl (control, 1:140. and 1:280) and
analyzed by HPLC, as detailed in the Materials and Methods section. The
fluorescent detector was set at excitation 321 nm and emission
465 nm. The molar ratio of the LPO:HOCl used for treatment is
mentioned in inset of each panel. This data are representative of three
independent experiments.
doi:10.1371/journal.pone.0027641.g008
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observed when oxy-Hb, hematin, MPO, as well as protoporphyrin
IX were treated with increasing concentrations of HOCl [36,37].
Collectively, this work demonstrates the ability of HOCl to
modulate heme destruction through oxidative cleavage of one or
more carbon-methene bridges of the tetrapyrrole moiety. We
suggest that this phenomenon may partially elucidate the
significant role played by HOCl in pathological conditions.
HOCl also mediates the heme destruction of LPO-Fe(II)-O2
complex through a mechanism that initially involves heme
oxidation, but otherwise the kinetics of heme destruction was
almost similar to those obtained for LPO-Fe(III) with HOCl.
Under these circumstances the oxidized form of the enzyme can
no longer bind oxygen but it can bind the OCl
2 molecule. Based
on our kinetic model illustrated in Fig. 9 (see also Table 1, for the
rate constants of each step), the three main pathways that lead to
the formation of LPO Compound III are: the direct reaction
between O2 and superoxide with LPO-Fe(II) and LPO-Fe(III),
respectively, or the addition of a slight molar excess of H2O2 to
LPO-Fe(III). The role of LPO Compound III in biological systems
is still unclear. The reverse rate constant (koff) of LPO-Fe(II)-O2
binding is significantly higher when compared with that of other
hemoproteins [16]. Several factors and conditions may account for
the high dissociation rate in LPO-Fe(II)-O2, including: the positive
trans effect contributed by the peroximal ligand, the heme pocket
microenvironment, and the geometry of Fe-O2 linkage. This
notion is consistent with earlier resonance Raman spectroscopy
studies, which showed that the u(Fe-O2) frequency for LPO was, to
a large extent, lower than those reported for related and relevant
hemoprotein model compounds [56] We believe that the high
dissociation rate of LPO-Fe(II)-O2 complex [16] is a key feature
that drives rapid oxidation and decomposition of the enzyme-O2
complex, and promotes generation of ligand-free LPO-Fe(III).
Previously, we have shown that the formation of an LPO-Fe-O2
complex intermediate in the catalytic mechanism of the enzyme
[16]. As such, low OCl
2 concentration might represent an
alternative pathway, whose biological function is to destabilize
LPO Compound III, an inactive form of the enzyme, and restore
its catalytic activity and rejoin the peroxidase cycle after the
removal of unwanted HOCl.
A reducing and denaturing SDS-PAGE showed different
degrees of protein aggregation as a function of HOCl concentra-
tion. The degree of LPO protein aggregation induced by HOCl
was much less than when hemoglobin/apohemoglobin or catalase
was treated with HOCl under identical experimental conditions.
In addition, globin aggregation in hemoglobin occurred indepen-
dently of iron presence. Indeed, previous studies by Chapman et.
Figure 9. A general kinetic scheme showing the influence of HOCl on the LPO catalytic cycle.
doi:10.1371/journal.pone.0027641.g009
Table 1. Rates for the reactions depicted in the kinetic model
in Fig. 9.
Step Rate References
k1 11 mm
21 s
21 [47]
k2 200 mm
21 s
21 [47]
k3 0.014 mm
21 s
21 Present study
k4 12.1 mm
21 s
21 Present study
k24 18 s
21 Present study
k5 1610
24 mm
21 s
21 Present study
k6 2. 2610
24 mm
21 s
21 [86]
k7 4610
24 mm
21 s
21 Present study
k8 0.0005 s
21 [12]
doi:10.1371/journal.pone.0027641.t001
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studies have shown that as a result of exposure to HOCl,
apohemoglobin undergoes aggregation and produces a regular
series of high molecular weight oligomers [57]. This change in the
protein structure in hemoglobin was facilitated by the formation of
protein carbonyls and possibly chloramines, along with methio-
nine oxidation, which altered the protein folding and, subsequent-
ly, the secondary/tertiary structure of the protein. The process of
aggregation was due to non-covalent interaction between the
exposed hydrophobic areas on neighboring molecules that
associate to form dimers and higher-molecular mass aggregates
[57]. Recent studies with intact hemoglobin have shown similar
patterns of protein aggregation in reducing SDS PAGE, except for
a distinct dimer band we observed, even at higher HOCl-Hb
ratios [36]. This process could lead to the formation of aggregated
proteins at sites of inflammation where MPO activity and
subsequently HOCl generation is enhanced, and may contribute
to tissue injury. Aggregated proteins are formed during aging [58],
in diabetes [59] and in neurodegenerative diseases, including
Creutzfeldt–Jacob disease, Huntington’s disease, Alzheimer’s
disease and Parkinson’s disease [60,61].
LPO Compound I preferentially catalyzes the 2-electron
oxidation of SCN
2, generating the corresponding HOSCN.
LPO Compound I may also oxidize SCN
2 through a two
sequential one-electron steps, forming Compound II and LPO-
Fe(III), respectively [62]. The ability of both LPO Compounds I
and II to employ SCN
2 as a 1e
2 substrate prevents LPO heme
destruction mediated by HOCl, and influences the nature of the
end products of the SCN
2 oxidation reaction. Our results clearly
showed that the protection of HOCl mediated LPO heme
degradation require a ratio of at least 4:1 HOCl:SCN
2 (Fig. 5).
One electron oxidation of SCN
2 yields unstable thiocyanate
radical, which then dimerizes to generate a labile short-lived
intermediate, thiocyanogen (SCN)2 [63,64]. The resulting (SCN)2
is rapidly hydrolyzed to generate either HOSCN/OSCN
2 or
CN
2 without the formation of HOSCN as an end product
[61,63,65,66]. Alternatively, SCN
2 can react directly with HOCl
to generate HOSCN [67]. Taken together, these studies suggest
that LPO may serve as a catalytic sink for HOCl, regulating its
bioavailability and function.
HOCl-mediated LPO heme destruction events are likely to
occur extracellularly. LPO is secreted from the goblet cells and
submucosal glands which is a major constituent of the mucus and
is very important constituent for maintaining anti-infective
properties of airway epithelium [68]. It is likely that MPO is
independently secreted into sites of inflammation from phagocytic
cells. In the airway, we believe that there is a balance between
HOCl and SCN
2. Disturbance of this balance allows LPO to
serve as a source of free iron. The normal SCN
2 concentration in
the plasma is ranging from 20 to 120 mM, while in airways
secretion it is about 460 mM [69,70]. But under certain
pathological conditions such as cystic fibrosis, the level of SCN
2
is known to be, as low as, 0.5 mM which disrupts the microbicidal
function of LPO [71–73]. Direct measurement of HOCl in the
airways has not been done and would be difficult since HOCl is
very labile and reactive. Using computational modeling the level of
HOCl generated from activated neutrophils has been estimated to
be 150–425 mM HOCl/hour and at sites of inflammation it has
been estimated to reach, as high as, 5 mM [74]. During airway
inflammation there is increased neutrophil influx and the
neutrophil count in the airway increases from 34.1610
3/mL to
115.7610
3/mL [73]. Also the MPO protein level increases to
4.68 nM from 0.12 nM [73]. This increased MPO leads to an
increase in HOCl production along with its subsequent damage to
the biomolecules. Indeed Van der vliet et. al., have shown that in
cystic fibrosis, MPO is the chief mediator of oxidative damage
within the respiratory tract [75]. They also suggested that the
localized MPO concentration could reach around 0.5–10 mM with
an estimated HOCl concentration of 760 mM [71]. Previous
studies have demonstrated that the airways of cystic fibrosis
patients contain increased amount of total iron and the iron-
binding protein ferritin [44,76]. This may explain why increased
polymorpho neutrophil (PMN) phagocytosis cannot prevent
Pseudomonas aeruginosa infection [44]. Increase in PMN influx will
lead to an increase in HOCl and increase free iron which will
accelerate P. aeruginosa growth. In related study, Agbai has shown
that high SCN
2 diets give rise to low incidence of sickle cell
anemia in Africans, while SCN
2 deficient American meals cause
increase number of cases of the disease in African-American
population [77].
We have obtained significant data demonstrating that HOCl
can mediate hemoproteins heme destruction and subsequent
liberate of free iron in complex biological systems such as intact
red blood cells, despite their extensive content of antioxidant such
as GSH/glutathione reductase, and catalase [36]. These antiox-
idant systems have been previously shown to be potent targets of
HOCl consumption. We are currently examining the role of
HOCl in destroying the RBC of sickle cell patients, a condition
known to be associated with higher plasma complement activation
and higher MPO levels, (Maitra & Abu-Soud, unpublished data).
Since the chemistry between heme and HOCl that we have
reported in this study is similar to that which occurs when
hemoglobin react with HOCl, this phenomenon may occur in
complex biological systems.
In summary, HOCl levels and LPO activity are apparently
coupled through complex interdependent pathways. The biolog-
ical consequences of HOCl-peroxidase interactions may have
broad implication for the regulation of local inflammatory,
infectious, and cardiovascular events in vivo. Increased HOCl
levels, the deficiency of potent HOCl scavengers such as taurine,
glutathione, and lycopene [78–80], or the deficiency of the natural
enzyme substrate, SCN
2, may contribute to infection and
inflammation by increasing catalytically active free iron levels
and enhancing bacterial development.
Materials and Methods
Materials
All materials used were of highest purity grade and used without
further purification. Sodium hypochlorite (NaOCl), ammonium
acetate (CH3COONH3), ferrozine, L-methionine, ascorbic acid,
methanol and trifluoroacetic acid (TFA) - HPLC grade, were
obtained from Sigma Aldrich (St. Louis, MO, USA). HPLC grade
acetonitrile (CH3CN) was obtained from EMD Chemicals Inc.
(Gibbstown, NJ, USA). Bovine LPO was obtained from
Worthington Bio-Chemistry Corp. (Lakewood, NJ, USA) and
used with further purification by sepharose column. Purity was
confirmed by demonstrating a RZ (Reinheitszahl) of .0.78 (A415/
A280), as well as SDS-PAGE analysis. LPO concentration was
determined spectrophotometrically by utilizing an extinction
coefficient of 112,000 M
21 cm
21 at 412 nm [81].
Absorbance Measurements
Absorbance spectra were recorded using a Cary 100 Bio UV–
visible spectrophotometer, at 25uC, pH 7.0. Experiments were
performed in a 1 mL phosphate buffer solution supplemented with
fixed amount of LPO (1.5 mM) and increasing concentrations of
HOCl (0, 25, 50, 100, 150, 175, 200, and 300 mM). To accomplish
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absorbance changes were recorded from 300 to 700 nm.
Rapid Kinetic Measurements
Kinetic measurements of HOCl-mediated LPO heme destruc-
tion were performed using a dual syringe stopped-flow instrument
obtained from Hi-Tech, Ltd. (Model SF-61). Measurements were
carried out under an aerobic atmosphere at 10uC following rapid
mixing of equal volumes of a buffer solution containing a fixed
amount of LPO (3 mM final) and a buffer solution containing
increasing concentration of HOCl. The time course of the
absorbance change was fitted to a single-exponential,
(Y=12e
2kt), or a double-exponential (Y=Ae
2k1t+Be
2k2t) func-
tion as indicated. Signal-to-noise ratios for all kinetic analyses were
improved by averaging at least six to eight individual traces. In
some experiments, the stopped-flow instrument was attached to a
rapid scanning diode array device (Hi-Tech) designed to collect
multiple numbers of complete spectra (200–800 nm) at specific
time ranges. The detector was automatically calibrated relative to
a holmium oxide filter, as it has spectral peaks at 360.8, 418.5,
446.0, 453.4, 460.4, 536.4, and 637.5 nm, which were used by the
software to correctly align pixel positions with wavelength.
High Performance Liquid Chromatography (HPLC)
analysis
HPLC analyses were carried out using a Shimadzu HPLC
system equipped with a SCL-10A system controller, with a binary
pump solvent delivery (LC-10 AD) module and a SIL-10AD auto-
injector connected to a SPD-M10A diode array detector (DAD)
and a RF-10A XL fluorescence detector. Alltech 5 mm particle
size, 4.66150 mm reverse-phase octadecylsilica (C18) HPLC
column was used. The photodiode array detector was set at
400 nm and the fluorescent detector was set at excitation 321 nm
and emission 465 nm to monitor the chromatogram. The column
was eluted at a flow rate of 1.0 mL/min with linear gradients of
solvents A and B (A, 0.1% TFA in water; B, 0.1% TFA in 80%
acetonitrile). The solvent gradient was as follows: 0 to 10 min, 55–
65%B; 10 to 14 min, 65–90% B; then the buffer B composition
dropped down to 55% within 14 to 24 min. After treatment of
LPO (1.5 mM) with HOCl (0 to 400 mM) for 2 hours, the reaction
was stoped with 5 molar excess of methionine, and 500 mL of the
reaction mixture was diluted with 500 mL of injection solvent (55%
B and 45% A) and 50 mL were injected. After the end of the run,
the system was equilibrated with 45% solvent A. Each sample was
analyzed in triplicate. After treatment with HOCl, the reaction
mixture was filtered through an Amicon Ultra-15 centrifugal filter
unit with Ultracel-10 membrane (from Millipore) with a 3-kDa
cut-off by centrifuging at 14,000 g for 30 min at 4uC.
Free iron analysis
Free iron release was measured colorimetrically by using the
ferrozine-based assay, following a slight modification of a
published method [82]. To 100 mL of the sample (LPO-HOCl
reaction mixture), 100 mL of ascorbic acid (100 mM) were added.
After 5 minutes of incubation at room temperature, 50 mLo f
ammonium acetate (16%) and the same volume of ferrozine
(16 mM) were added to the mixture and mixed well. Again, after
5 minutes of incubation at room temperature, the absorbance was
measured at 562 nm. A standard curve prepared by using
ammonium Fe(III) sulfate was used for the calculation of free
iron concentration. Final concentrations of the additives are as
follows, ascorbic acid-33.33 mM, ammonium acetate 5.3%, and
ferrozine 5.3 mM.
SDS-PAGE
Samples of LPO (1.5 mM) were mixed with increasing HOCl
concentrations (0 to 300 mM) and incubated for two hours at room
temperature. After reaction completion, methionine (5-fold of the
final HOCl concentration) were added to eliminate excess HOCl,
and 10 mg of LPO (from the reaction mixtures) were incubated
with Laemmli buffer [83] containing 63 mM Tris–HCl (pH 6.8),
2% (w/v) SDS, 10% (w/v) glycerol, 0.0025% (w/v) bromophenol
blue, and 10% (v/v) 2-mercaptoethanol. The samples were boiled
for 5 minutes at 100uC before loading, and gel electrophoresis was
performed for 2 h at a constant voltage of 60 V on 4–12%
gradient gels. Three sets of gels were run at room temperature on
different days. The gels were then stained with Coomassie blue for
24 hours, destained in methanol/acetic acid to remove back-
ground and digitalized. The band intensity of the 77 KDa,
corresponding to LPO was quantified using ImageJ (NIH) software
and the intensity of the control (untreated LPO) was compared to
that of HOCl treated samples. Further the ratio of the band
intensities between LPO 77 KDa and the higher molecular weight
aggregates were also plotted as a function of HOCl concentration.
Relative amounts of protein were estimated by densitometric
analysis of the images using Image J software from the NIH [32].
Solution preparation
HOCl preparation - HOCl was prepared following a slight
modification of a published method [84]. Briefly, a stock solution of
HOCl was prepared by adding 1 ml NaOCl solution to 40 ml of
154 mM NaCl, and the pH was adjusted to around 3 by adding HCl.
The concentration of active total chlorine species in solution
expressed as [HOCl]T (where [HOCl]T=[HOCl]+[Cl2]+[-
Cl3
2]+[OCl
2]) in 154 mM NaCl was determined by converting all
t h ea c t i v ec h l o r i n es p e c i e st oO C l
2 by adding a bolus of 40 mLo f
5 M NaOH and measuring the concentration of OCl
2.T h e
concentration of OCl
2 was determined spectrophotometrically at
292 nm (e=362 M
21 cm
21) [85]. As HOCl is unstable, the stock
solution was freshly prepared on a daily basis, stored on ice, and used
within one hour of preparation. For further experiments, dilutions
were made from the stock solution using 200 mM phosphate buffer
pH 7, to give working solutions of lower HOCl concentration.
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